Business Wire

MA-OPTIKOS

Share
Optikos Announces New Optical Testing Products to Meet Automotive Imaging Demands

Optikos Corporation introduced three new products to its OpTest® and Meridian® lens and camera metrology product lines, developed to address the specific requirements for testing and image capture conditions in the field of automotive imaging.

Optikos has a long history of pioneering the development and commercialization of test equipment for the evaluation of lenses and cameras, including the OpTest® and LensCheck product families, widely regarded as the gold standard for assessing the image quality of lens assemblies; and the Meridian product line, for measuring the performance of an assembled camera. The Company is recognized not only for its comprehensive range of standard products, but also its readiness to customize hardware and software to suit a customer’s particular requirements such as those demanded in automotive imaging applications.

With two of its newest products, Optikos has extended its expertise in measuring the effects of stray light in lenses to camera assemblies—with the Meridian camera testing line now including products that serve as sources for measuring Veiling Glare Index (VGI) and Glare Spread Function (GSF).

VGI measurements are useful as a measure of diffuse irradiance on the image plane, and require a uniformly illuminated background field populated with one or more dark objects. The new Meridian VGI source is a customizable hemispherical integrating sphere into which light traps of various sizes may be fitted; and enables the customer to specify the sizes and locations of the light traps according to the characteristics of the camera assemblies to be tested. The system is illuminated using white LEDs, the intensity of which may be remotely controlled.

Glare Spread Function testing evaluates the severity of ghost reflections or other prominent stray light artifacts that form concentrated irradiation patterns. The new Meridian Sol-55 projector addresses this need with a modular design, and features interchangeable object aperture drawers for controlling the angular extent of the projected target, and an aperture wheel that controls the numerical aperture of the illumination through the object aperture. “The unique design avoids overfilling the lens under test and creating a secondary source of stray light from adjacent scattering surfaces; while illumination is provided by a high intensity white LED which can be remotely controlled for high dynamic range measurements,” said David Imrie, Optikos Chief Technology Officer.

Meridian Sol-55 projectors are designed to be flexibly mounted at pre-determined field points with respect to the device-under-test in rigid assemblies that form a Meridian Sunfield system. They are distinguished from Meridian Starfield assemblies of Static Target Projectors (STPs) used in image quality (MTF) testing of cameras.

In addition to stray light, temperature extremes pose a significant challenge for image sensor performance in automotive cameras. Optikos has been testing lenses across a range of temperatures in its IQ Lab™ Optical Testing Service since 2017, and first productized this process for testing lenses up to 150mm with its Thermal Module TM-1150 system.

The new TC-1065 is a thermal chamber used for lens testing that extends the maximum size of lenses that may be tested over a range of temperatures on a LensCheck system, complementing the smaller TC-1050 and TC-1010 products also available in the product line. In order to optimize the thermal performance, the thermal chamber is generally sized to match the dimensions of the lenses with which it will be used.

Optikos will be exhibiting at AutoSens Brussels 2022 on October 12-14th. To learn more about Optikos solutions for automotive imaging, see contact details below.

About Optikos

The Optical Engineering Experts®—Optikos provides leading-edge applications of optical technology to organizations worldwide. For customers who require optical testing and image quality assessment of lens and camera systems, we offer an advanced line of standard and custom metrology products as well as in-house IQ Lab™ Optical Testing Services. We offer product development services that include a broad range of engineering, contract manufacturing, and assembly capabilities. Our broad skill set, including optics, mechanics, electronics, automation, and software systems, enables us to quickly understand our customers' unique technical requirements and provide a flexible and scalable resource. Applications range from medical devices and diagnostics to aerial imaging, defense, automotive cameras, and well beyond.

For more information, visit optikos.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005764/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye